Martine Rothblatt, United CEO (Jack Plunkett, AP Images)

Unit­ed ax­es PAH pro­gram Trevyent, once bought for cheap in ac­qui­si­tion of a ri­val, af­ter FDA feed­back

About three years af­ter ac­quir­ing SteadyMed and its ex­per­i­men­tal pul­monary ar­te­r­i­al hy­per­ten­sion drug Trevyent, Unit­ed Ther­a­peu­tics has de­cid­ed to kick the pro­gram to the curb.

In an 8-K form filed with the SEC on Tues­day, Unit­ed re­vealed that they are shut­ting down de­vel­op­ment of Trevyent af­ter re­ceiv­ing feed­back from the FDA last week. The move marks the end of a long and bumpy road for the pro­gram, which had pre­vi­ous­ly earned an RTF in 2017 and a CRL last April, as Unit­ed moves for­ward with new Ty­va­so for­mu­la­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.